Human protein reference database—2006 update

Human Protein Reference Database (HPRD) () was developed to serve as a comprehensive collection of protein features, post-translational modifications (PTMs) and protein–protein interactions. Since the original report, this database has increased to >20 000 proteins entries and has become the largest database for literature-derived protein–protein interactions (>30 000) and PTMs (>8000) for human proteins. We have also introduced several new features in HPRD including: (i) protein isoforms, (ii) enhanced search options, (iii) linking of pathway annotations and (iv) integration of a novel browser, GenProt Viewer (), developed by us that allows integration of genomic and proteomic information. With the continued support and active participation by the biomedical community, we expect HPRD to become a unique source of curated information for the human proteome and spur biomedical discoveries based on integration of genomic, transcriptomic and proteomic data

Density, Viscosity, and Interfacial Tension of Binary Mixture of Tri-<i>iso</i>-amyl Phosphate (TiAP) and <i>n</i>‑Dodecane: Effect of Compositions and Gamma Absorbed Doses

The changes in interfacial tension against water, density, and coefficient of viscosity of a binary mixture of tri-<i>iso-</i>amyl phosphate (TiAP) and <i>n-</i>dodecane have been measured before and after gamma radiolysis. Density, viscosity, and interfacial tension of binary mixtures are additive functions of mole fractions of TiAP and gamma absorbed dose, which respectively form a plane in three-dimensional plots of linear–linear–linear, log_e–log_e–linear, and log_e–log_e–linear scales. Logarithmic interfacial tension also forms a three-dimensional plane with density and viscosity in log_e–linear–linear plot. Redlich–Kister type equations (RK-eq) have been introduced to model excess properties of binary mixtures, where a second independent variable is the absorbed dose. The parametric coefficients of RK-eqs pertaining to excess molar volume, viscosity deviations, and interfacial tension deviations of the mixtures are linear functions of the absorbed dose. Molecular interactions between solute–solute and solute–solvent have also been quantified in terms of apparent molar volume at infinite dilution, among others

Plasma proteome database as a resource for proteomics research

Plasma is one of the best studied compartments in the human body and serves as an ideal body fluid for the diagnosis of diseases. This report provides a detailed functional annotation of all the plasma proteins identified to date. In all, gene products encoded by 3778 distinct genes were annotated based on proteins previously published in the literature as plasma proteins and the identification of multiple peptides from proteins under HUPO's Plasma Proteome Project. Our analysis revealed that 51% of these genes encoded more than one protein isoform. All single nucleotide polymorphisms involving protein-coding regions were mapped onto the protein sequences. We found a number of examples of isoform-specific subcellular localization as well as tissue expression. This database is an attempt at comprehensive annotation of a complex subproteome and is available on the web at http://www.plasmaproteomedatabase.org

Statistics pertaining to HPRD growth, experimental types for protein–protein interactions and a breakdown of PTMs

<p><b>Copyright information:</b></p><p>Taken from "Human protein reference database—2006 update"</p><p>Nucleic Acids Research 2005;34(Database issue):D411-D414.</p><p>Published online 28 Dec 2005</p><p>PMCID:PMC1347503.</p><p>© The Author 2006. Published by Oxford University Press. All rights reserved</p> () Growth of HPRD over the last 3 years with respect to protein entries, protein–protein interactions and PTMs. () Distribution of protein–protein interactions in HPRD based on the type of the experimental method. () Distribution of various types of PTMs in HPRD. The percentage of the respective PTM is indicated only when it is greater than or equal to 2

Development of Budesonide Microparticles Using Spray-Drying Technology for Pulmonary Administration: Design, Characterization, In Vitro Evaluation, and In Vivo Efficacy Study

The purpose of this research was to generate, characterize, and investigate the in vivo efficacy of budesonide (BUD) microparticles prepared by spray-drying technology with a potential application as carriers for pulmonary administration with sustained-release profile and improved respirable fraction. Microspheres and porous particles of chitosan (drug/chitosan, 1:2) were prepared by spray drying using optimized process parameters and were characterized for different physicochemical parameters. Mass median aerodynamic diameter and geometric standard deviation for conventional, microspheres, and porous particles formulations were 2.75, 4.60, and 4.30 µm and 2.56, 1.75, and 2.54, respectively. Pharmacokinetic study was performed in rats by intratracheal administration of either placebo or developed dry powder inhalation (DPI) formulation. Pharmacokinetic parameters were calculated (Ka, Ke, Tmax, Cmax, AUC, and Vd) and these results indicated that developed formulations extended half life compared to conventional formulation with onefold to fourfold improved local and systemic bioavailability. Estimates of relative bioavailability suggested that developed formulations have excellent lung deposition characteristics with extended T1/2 from 9.4 to 14 h compared to conventional formulation. Anti-inflammatory activity of BUD and developed formulations was compared and found to be similar. Cytotoxicity was determined in A549 alveolar epithelial cell line and found to be not toxic. In vivo pulmonary deposition of developed conventional formulation was studied using gamma scintigraphy and results indicated potential in vitro–in vivo correlation in performance of conventional BUD DPI formulation. From the DPI formulation prepared with porous particles, the concentration of BUD increased fourfold in the lungs, indicating pulmonary targeting potential of developed formulations